

Associations of central aortic pressure and brachial blood pressure with flow mediated dilatation in apparently healthy Japanese men: The Circulatory Risk in Communities Study (CIRCS).

著者別名	山岸 良匡
journal or publication title	Atherosclerosis
volume	259
page range	46-50
year	2017-04
権利	(C) 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
URL	http://hdl.handle.net/2241/00146799

doi: 10.1016/j.atherosclerosis.2017.02.024

1 **ASSOCIATIONS OF CENTRAL AORTIC PRESSURE AND BRACHIAL**
2 **BLOOD PRESSURE WITH FLOW MEDIATED DILATATION IN**
3 **APPARENTLY HEALTHY JAPANESE MEN: THE CIRCULATORY**
4 **RISK IN COMMUNITIES STUDY (CIRCS)**

5
6 Keyang Liu¹, Renzhe Cui¹, Ehab S Eshak^{1,2}, Meishan Cui¹, Jia-Yi Dong¹,
7 Masahiko Kiyama³, Takeo Okada³, Akihiko Kitamura^{3,4}, Mitsumasa Umesawa⁵,
8 Kazumasa Yamagishi⁶, Hironori Imano¹, Tetsuya Ohira⁷, Hiroyasu Iso¹

9 1. Public Health, Department of Social Medicine, Osaka University Graduate
10 School of Medicine

11 2. Department of Public Health and Preventive Medicine, Minia University,
12 Egypt

13 3. Osaka Center for Cancer and Cardiovascular Disease Prevention

14 4. Tokyo Metropolitan Institute of Gerontology

15 5. Department of Public Health, Dokkyo Medical University, School of Medicine

16 6. Departments of Public Health Medicine, Faculty of Medicine, University of
17 Tsukuba

18 7. Radiation Medical Science Center for the Fukushima Health Management
19 Survey, Fukushima Medical University

20 **Number of tables:2. Number of figures:0.**

21
22
23 *Correspondence to:*

24 Professor Hiroyasu Iso, M.D, Ph.D.

25 Public Health, Department of Social Medicine,

26 Osaka University Graduate School of Medicine

27 2-2 Yamadaoka, Suita-shi, Osaka, 565-0871 Japan.

28 Tel: +81-6-6879-3911; Fax; +81-6-6879-3919

29 E-mail: iso@pbhel.med.osaka-u.ac.jp

30 **Highlights**

31 • We examined the associations of central systolic aortic pressure and brachial
32 systolic pressure with flow mediated dilatation in apparently healthy Japanese
33 men.

34 • Higher central aortic pressure rather than higher brachial blood pressure was
35 associated with lower flow mediated dilatation; the association was evident for
36 men without antihypertensive medication.

37 • Our finding suggests that central systolic aortic pressure, rather than brachial
38 systolic blood pressure, is a useful marker for endothelial dysfunction in men.

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56 **Background and aims.** Endothelial dysfunction is considered the first stage in
57 the development of atherosclerosis and cardiovascular disease, and brachial flow-
58 mediated dilation (FMD) is a measure of endothelial function. It is uncertain
59 which of central systolic aortic pressure (CAP) or brachial systolic blood
60 pressure (SBP) is more strongly associated with FMD. Therefore, we examined
61 the correlations of CAP and SBP with FMD in Japanese men.

62 **Methods.** The study subjects comprised 507 male volunteers aged 30–79 years
63 that were residents in two communities under the Circulatory Risk in
64 Communities Study (CIRCS) between 2013 and 2015. The low percent change
65 of FMD (%FMD) $\leq 5.0\%$ after 5 minutes of reactive hyperemia evaluated by the
66 brachial artery was used to assess endothelial dysfunction. Values of CAP and
67 SBP were divided into tertiles, with the lowest tertile used as a reference.

68 **Results.** After adjustment for cardiovascular risk factors, the multivariable odds
69 ratio (95% CI) of low FMD for the highest versus the lowest tertile of CAP was
70 1.5(0.9–2.6) for total subjects and 1.3(0.7–2.5) for those with and 2.4(1.2–4.8)
71 for those without antihypertensive medication use. The corresponding odd ratios
72 for the highest versus lowest tertile of SBP were 0.9(0.5–1.5), 0.8(0.3–2.2), and
73 1.3(0.7–2.5).

74 **Conclusions.** Higher CAP levels were associated with low FMD for men without
75 antihypertensive medication, but such an association was not found for SBP
76 levels. (word count: 227)

77 **Key words:** Central aortic pressure ■ Endothelial function ■ Japanese men ■

78 Cross sectional study

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100 **1. Introduction**

101 Cardiovascular diseases remain the major cause of morbidity and mortality in
102 developed countries, with atherosclerosis being the leading underlying cause (1).
103 Endothelial dysfunction is considered the first stage in the development of
104 atherosclerosis and cardiovascular disease (2, 3). Endothelial cells form the inner
105 lining of all blood vessels and play a central role in vascular homeostasis; they
106 respond to stimuli, such as hemodynamic changes or blood-borne signals by
107 releasing vasoactive substances (4). Brachial flow-mediated dilation (FMD) is a
108 measure of the release of nitric oxide by the endothelium due to a transient flow
109 stimulus (5) and low brachial FMD was regarded as a cardiovascular disease risk
110 factor (4, 5).

111 Hypertension is a recognized risk factor for the development of atherosclerosis
112 and cardiovascular disease (6-8). Central systolic aortic pressure (CAP) has been
113 reliably determined by mathematically transforming the radial artery pulse
114 waveform to the aortic pulse waveform (9-10). Several studies have also reported
115 that CAP levels were strongly associated with risk of mortality from
116 cardiovascular disease (11, 12). The Circulatory Risk in Communities Study
117 (CIRCS) of 3, 002 Japanese men and women reported that CAP levels were
118 correlated more strongly with cardiovascular risk factors than brachial systolic
119 blood pressure (SBP) levels (13). However, evidence for the correlation of CAP
120 with FMD is limited. Additionally, to date, it is unclear which of CAP or SBP is
121 more strongly associated with flow-mediated dilatation. In this study, we

122 investigated the relationship of CAP and SBP with FMD in the general

123 population.

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144 **2. Materials and Methods**

145 2.1. Subjects

146 FMD and CAP measurements were conducted in two communities of the CIRCS,
147 a dynamic cohort study of the Japanese population: Yao City, Osaka Prefecture
148 and Ikawa town, Akita Prefecture under a nationwide study. We recruited 507
149 men aged 30–79 years one by one from January 2013 to May 2015 from
150 participants who underwent annual cardiovascular risk surveys. Informed consent
151 was obtained from community representatives based- on guidelines of the
152 Council for International Organizations of Medical Science to perform an
153 epidemiological study (14). The study protocol was approved by the Ethics
154 Committee of the Osaka University.

155 2.2. Measurement of FMD and CAP

156 All participants had five minutes of rest in the seated posture, using a standard
157 protocol (15). FMD was measured with high-resolution ultrasonography and
158 forearm occlusive cuff by technicians. High-resolution ultrasound with a 10-
159 MHz linear array transducer was used to record longitudinal images of the right
160 brachial artery. This transducer system can accurately capture and track the edge
161 of target artery automatically once the probe is placed at the proper position. To
162 standardize the position of the probe, we used a specially designed arm-rest and
163 probe holder. The brachial artery diameter at baseline was measured by this
164 system and then the brachial cuff was inflated to 50mm Hg above SBP for 5

165 minutes and deflated. Computer-assisted analysis software (UNEX Co. Ltd.,
166 Nagoya, Japan) was used to determine brachial artery diameter semi-
167 automatically, as previously described (16).

168 The baseline longitudinal image of the artery was acquired for 30 seconds, after
169 which the blood pressure cuff was inflated to 50 mmHg above systolic pressure
170 for 5 minutes. FMD change (%FMD) was defined by the following
171 formula: %FMD = ((maximal artery lumen diameter after cuff release-artery
172 lumen diameter at baseline)/artery-lumen diameter at baseline) ×100, according
173 to published guidelines for determining endothelial function (17). The coefficient
174 of inter-observer variability for FMD measurements in our laboratory was 5.7 %,
175 while that of intra-observer variability were 11.1% apart from 2 months and
176 10.8% apart from 4 months. In previous studies, the coefficient of inter-observer
177 variability for FMD measurement was 1.3% to 3.5% (18, 19), and that for intra-
178 observer variability was 15.6% apart from 48 hours and 18.3% apart from 3
179 months (20).

180 CAP was measured by technicians with an automated tonometer, HEM-9000AI
181 (Omron, Healthcare Co., Kyoto, Japan). A previous clinical study used both
182 HEM-9000AI and standard cardiac catheterization to examine the validity and
183 reproducibility of CAP levels among 18 hypertension patients aged 47–78 years.
184 The correlation coefficient was 0.95 ($p < 0.001$) between CAP levels by the two
185 measurement systems, and 0.93 ($p < 0.001$) between the repeated CAP
186 measurement by HEM-9000AI (6).

187 2.3. Measurement of cardiovascular risk factors

188 We previously reported the protocols for measuring cardiovascular risk factors,
189 such as blood pressure, serum lipids, body mass index (BMI), assessment of
190 smoking and drinking habits, hypertension, and diabetes mellitus (10, 21, 22).
191 Height in stocking feet and weight in light clothing were measured. Body mass
192 index (BMI) (kg/m^2) was calculated as weight in kilograms divided by height in
193 square meters. Trained observers measured SBP and diastolic blood pressure
194 (DBP) using a standard mercury sphygmomanometer on the right arm after
195 participants had rested for 5 minutes (23). An interview was conducted to
196 confirm information on habits, including drinking status, tobacco status,
197 hypertension, and diabetes mellitus medication use. For drinking status, persons
198 who reported consuming 0.3 gō (equivalent to 7 grams of ethanol) or more per
199 week were regarded as current drinkers. Former drinkers were defined as
200 abstainers for the previous 3 months or more. Trained interviewers also
201 determined information on smoking status, use of antihypertensive agents, and
202 medical history. Persons who smoked ≥ 1 cigarette per day were defined as
203 current smokers.

204 Blood samples were obtained on the same day as annual cardiovascular risk
205 surveys from participants and the serum was separated immediately.

206 Measurements of serum triglycerides were performed using a fluorometric
207 method by an Autoanalyzer II (Technicon, Tarrytown, NY, U.S.A.), while total
208 cholesterol and high density lipoprotein (HDL)-cholesterol measurements were

209 performed at the Osaka Medical Center for Health Science and Promotion lipid
210 reference laboratory, a certified member of the US National Cholesterol
211 Reference Method Laboratory Network (CRMLN), using enzymatic methods by
212 an auto analyzer Olympus AU 2700 (24). Serum glucose measurements were
213 performed by the hexokinase method, using the same instrument. Diabetes
214 mellitus was defined as a fasting glucose level of ≥ 7.8 mmol/L, a non-fasting
215 glucose level of ≥ 11.1 mmol/L, or use of medication for diabetes mellitus (25).
216 Hypertension was defined as SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, or use of
217 antihypertensive medication (26).

218 2.4. Statistical analysis

219 We defined the low FMD as $\%FMD \leq 5.0$ (lowest 30 percentile) based on
220 previous reports that used the receiver-operating characteristic analysis (27, 28).
221 Values of cardiovascular risk factors in subjects with $\%FMD \leq 5.0$ and > 5.0 are
222 presented as mean \pm standard deviation (SD) or proportions (%). The odd ratios
223 (OR) with the respective 95% confidence intervals (CIs) of the low FMD were
224 calculated according to tertiles of and 1-SD increment of CAP and SBP levels, by
225 using logistic regression analysis, after adjusting for age in one model, and
226 further adjustment for potential confounding factors including area of residence,
227 heart rate, brachial artery baseline diameter, total serum cholesterol, serum
228 triglycerides, history of diabetes mellitus, drinking status and smoking status.
229 The analyses were repeated by stratifying antihypertensive medication use.
230 All statistical analyses were performed with SAS version 9.4 software (SAS

231 Institute Inc., Cary, NC, USA). All probability values for statistical tests were
232 two-tailed and values of $p < 0.05$ were regarded as statistically significant.

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253 **3. Results**

254 The characteristics of 507 Japanese men are summarized in Table 1. The mean
255 values of %FMD, age and BMI were 6.7, 54.1 years and 24.2kg/m², respectively.
256 Compared with participants in the group of %FMD≤5, those in the group
257 of %FMD>5 had lower CAP, lower SBP levels and smaller brachial artery
258 baseline diameter, and were less likely to be drinkers, diabetics and hypertensive.

259 The ORs (95% CI) of the low FMD according to tertiles and 1-SD increment
260 for CAP and SBP levels are given in Table 2. Among total 507 subjects, the
261 multivariable ORs (95% CI) of the low FMD was 1.5(0.9–2.6) for the highest
262 versus lowest tertiles of CAP, and 1.2(1.0-1.5) for 1-SD increment (16.3 mmHg)
263 of CAP levels; while were 0.9(0.5–1.5) for the highest versus lowest tertiles of
264 SBP, and 1.0(0.8-1.3) for 1-SD increment (13.9 mmHg) of SBP levels.

265 When these associations were stratified by antihypertensive medication use,
266 significant positive associations between CAP and the low FMD were observed
267 primarily in subjects without antihypertensive medication use; the multivariable
268 ORs (95%CI) of the low FMD was 2.4(1.2–4.8) for the lowest versus highest
269 tertiles and 1.3(1.0-1.7) for 1-SD increment of CAP levels. There were no
270 difference in the associations between SBP and low FMD in participants with
271 and without the use of antihypertensive medication.

272

273

274

275 **4. Discussion**

276 In the present community-based study of 507 Japanese men aged 30–79 years,
277 CAP, but not brachial SBP, levels were correlated with the low FMD. The
278 association between CAP and low FMD levels was evident for men who did not
279 use antihypertensive medications.

280 Low FMD is a surrogate marker of early atherosclerosis in Japanese (29),
281 American (30), and European subjects (31). In a clinical study of 384 patients
282 with suspected cardio metabolic disorders, %FMD was significantly reduced in
283 patients with nonalcoholic fatty liver disease, diabetes, history of coronary heart
284 disease, metabolic syndrome, and in those taking antihypertensive drugs (31).
285 The Multi-Ethnic Study of Atherosclerosis for 2,936 men and women (mean age
286 61 years) showed that a 1-SD (2.8%) increase in %FMD values was associated
287 with lower risk of incident auricular fibrillation [Hazard ratio (HR) =0.84,
288 95%CI=0.70, 0.99], suggesting that markers of endothelial dysfunction
289 contributes to the pathogenesis of auricular fibrillation (30).

290 To our knowledge our study is the first to show that CAP levels were associated
291 more with reduced %FMD than SBP levels in men without use of
292 antihypertensive medication. Lind L has reported that CAP measurement was not
293 superior over traditional blood measurements regarding its relation to
294 endothelium-dependent vasodilatation or FMD (32). However, that study was
295 conducted only among elder participates over 70 years old. It was previously
296 shown that the absolute difference between aortic and brachial systolic pressures

297 declined with age (<20y up to 69 years) and then the difference plateaued after
298 ages \geq 70 years (33). Our study supports the previous finding from a clinical study
299 of 201 type 2 diabetes patients that an ankle-brachial index, a surrogate marker of
300 atherosclerosis, was more strongly correlated with CAP than SBP levels (CAP:
301 $r=0.162$, $p=0.04$, SBP: $r=0.083$, $p=0.30$) (34). Compared with a 10 mmHg
302 increment of SBP, the same increment of CAP was more strongly associated with
303 mortality risk from cardiovascular disease in a cohort study of normotensive and
304 untreated hypertensive Taiwanese; the multivariable HR (95% CI) of
305 cardiovascular mortality was 1.34(1.10–1.49) for CAP and 0.96(0.79–1.16) for
306 SBP (12).Our previous study found that CAP levels were associated with
307 subclinical damage expressed by minor ST-T ECG abnormalities (8).
308 Furthermore, a clinical study of 146 hypertensive patients reported that left
309 ventricular mass change was more strongly correlated with CAP than SBP (35).
310 These findings support CAP as a more sensitive marker for the loading
311 conditions on the heart and coronary arteries than SBP.
312 In the current study, the lack of association between CAP levels with %FMD
313 among subjects with antihypertensive medication use may be due to the dilution
314 of association after lowering CAP levels by various amounts. On the other hand,
315 the lack of association between SBP levels and %FMD in total subjects
316 regardless of antihypertensive medication use might probably due to the small
317 number of severe high blood pressure patients (SBP \geq 160 mmHg, $n=21$).
318 The strengths of the present study include the use of a noninvasive technique

319 for measuring CAP and FMD and the standardized measurements of other
320 cardiovascular risk factors in community population-based samples (22).
321 However, this study has several limitations as follows: first, details of
322 antihypertensive drug treatment were not available. Antihypertensive drugs such
323 as calcium channel antagonist, ACE-inhibitors and AT1-receptor antagonists can
324 improve endothelial function (36). However, we could not investigate whether
325 the lack of association between CAP levels and reduced %FMD in men with
326 antihypertensive medication use might be attributable to the effects of those
327 drugs or not. Second, reduced %FMD was the only indicator for endothelial
328 dysfunction in the current study; no data were available for nitrate-induced
329 vasodilatation. Last, our subjects were not recruited randomly, but they were
330 selected consecutively, and thus generalizability of our findings is limited. We
331 also were unable to include women in the current analysis because of very small
332 sample size, and further investigation will be necessary.

333 In conclusion, higher CAP levels were associated with low FMD for men
334 without antihypertensive medication, but such an association was not found for
335 SBP levels.

336

337 **Conflict of interest**

338 None declared.

339 **Financial support**

340 This study was supported by Grant-in-Aid for Scientific Research C (No.

341 25490790 in 2012-2014) from the Ministry of Health, Education, Culture, Sports,
342 Science and Technology, Japan.

343 **Author contributions**

344 Keyang Liu, Renzhe Cui, Ehab S. Eshak, Jia-Yi Dong, Meishan Cui and
345 Masahiko Kiyama participated in the study design and data collection; Keyang
346 Liu, Renzhe Cui and Ehab S. Eshak analyzed the data; Keyang Liu, Renzhe Cui,
347 Akihiko Kitamura and Hiroyasu iso participated in interpretation of data and
348 drafting of the manuscript; Keyang Liu, Renzhe Cui and Ehab S. Eshak provided
349 statistical expertise. Takeo Okada, Akihiko Kitamura, Mitsumasa Umesawa,
350 Kazumasa Yamagishi, Hironori Imano, Tetsuya Ohira and Hiroyasu Iso
351 participated in the study concept and design, acquisition of data and
352 interpretation of data, and critical revision of the manuscript.

353 **Acknowledgements**

354 The authors are grateful to Haytham A. Sheerah, Osaka University for his
355 contribution to this study. The full member list of the CIRCS Investigators is
356 presented in Appendix.

357 **Appendix**

358 The CIRCS study is a collaborative study managed by the Osaka Center for
359 Cancer and Cardiovascular Disease Prevention, University of Tsukuba, Osaka
360 University and Ehime University. The authors thank the CIRCS investigators
361 who contributed to this study: Professor Emeritus Yoshio Komachi (University of
362 Tsukuba), Professor Emeritus Hideki Ozawa (Medical College of Oita), Former

363 professor Minoru Iida (Kansai University of Welfare Sciences), Professor
364 Emeritus Takashi Shimamoto (University of Tsukuba), Dr. Yoshinori Ishikawa
365 (Consultant of Osaka Center for Cancer and Cardiovascular Disease Prevention),
366 Professor Yoshihiko Naito (Mukogawa Women's University), and Professor
367 Tomonori Okamura (Keio University).

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385 **References**

- 386 1. Fuster V, Kelly BB, Vedanthan R. Global cardiovascular health: urgent need
387 for an intersectoral approach. *J Am Coll Cardiol.* 2011; 58:1208-1210
- 388 2. Simsek H, Sahin M, Gunes Y, Akdag S, Akil MA, et al. A novel
389 echocardiographic method as an indicator of endothelial dysfunction in
390 patients with coronary slow flow. *Eur Rev Med Pharmacol Sci.* 2013; 17:689-
391 693
- 392 3. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, et al. Predictive value
393 of brachial flow-mediated dilation for incident cardiovascular events in a
394 population-based study: the multi-ethnic study of atherosclerosis. *Circulation.*
395 2009; 120:502-509
- 396 4. Widlansky ME, Gokce N, Keaney Jr JF, Vita JA. The clinical implications of
397 endothelial dysfunction. *J Am Coll Cardiol.* 2003; 42:1149-1160
- 398 5. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, et al. Predictive Value
399 of Brachial Flow-Mediated Dilation for Incident Cardiovascular Events in a
400 Population-Based Study. *Circulation.* 2009; 120: 502-509
- 401 6. Obuchowicz A, Książewska M, Zmudzińska-Kitczak J, Urban K, Gonciarz-
402 Majda A. Concentrations of tumour necrosis factor- α and its soluble receptors
403 in the serum of teenagers with atherosclerosis risk factors: obesity or obesity
404 combined with hypertension. *J Pediatr Endocrinol Metab.* 2014; 27:1209-1212
- 405 7. Whelton PK. Sodium, potassium, blood pressure, and cardiovascular disease
406 in humans. *Curr Hypertens Rep.* 2014;16:465

- 407 8. Cui R, Li Y, Krisztina G, Yamagishi K, Umesawa M, et al. An association
408 between central aortic pressure and subclinical organ damage of the heart
409 among a general Japanese cohort: Circulatory Risk in Communities Study
410 (CIRCS). *Atherosclerosis*. 2014; 232:94-98
- 411 9. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship
412 between radial and central arterial pulse wave and evaluation of central aortic
413 pressure using the radial arterial pulse wave. *Hypertens Res* 2007; 30:219-228
- 414 10. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for
415 estimating ascending aortic pressure from the radial artery pressure waveform.
416 *Hypertension*. 2001; 38:932-937
- 417 11. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, et al. Central
418 pressure more strongly relates to vascular disease and outcome than does
419 brachial pressure: the Strong Heart Study. *Hypertension*. 2007; 50:197-203
- 420 12. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, et al. Central or
421 peripheral systolic or pulse pressure: which best relates to target organs and
422 future mortality? *J Hypertens*. 2009; 27:461-7
- 423 13. Cui R, Li Y, Krisztina G, Yamagishi K, Umesawa M, et al. An association
424 between central aortic pressure and subclinical organ damage of the heart
425 among a general Japanese cohort: Circulatory Risk in Communities Study
426 (CIRCS). *Atherosclerosis*. 2014; 232:94-8
- 427 14. International guidelines for ethical review of epidemiological studies. *Law*
428 *Med Health Care*. 1991; 19: 247-258

- 429 15. Kohara K, Tabara Y, Oshiumi A, Miyawaki Y, Kobayashi T, et al. Radial
430 augmentation index: a useful and easily obtainable parameter for vascular
431 aging. *Am J Hypertens.* 2005; 18:11S-14S
- 432 16. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, et al. Relationship
433 between flow-mediated vasodilation and cardiovascular risk factors in a large
434 community-based study. *Heart.* 2013; 99: 1837-1842
- 435 17. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, et
436 al. International Brachial Artery Reactivity Task Force. Guidelines for the
437 ultrasound assessment of endothelial-dependent flow-mediated vasodilation of
438 the brachial artery: a report of the International Brachial Artery Reactivity
439 Task Force. *J Am Coll Cardiol.* 2002; 39: 257-265
- 440 18. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, et al. Association of
441 cardiovascular risk factors and endothelial dysfunction in Japanese
442 hypertensive patients: implications for early atherosclerosis. *Hypertens Res.*
443 2002; 25: 475-480
- 444 19. Suzuki K, Elkind MS, Boden-Albala B, Jin Z, Berry G, et al. Moderate
445 alcohol consumption is associated with better endothelial function: a cross
446 sectional study. *BMC Cardiovasc Disord.* 2009, 9: 8. doi: 10.1186/1471-2261-
447 9-8
- 448 20. Charakida M, de Groot E, Loukogeorgakis SP, Khan T, Lüscher T, et al.
449 Variability and reproducibility of flow-mediated dilatation in a multicentre
450 clinical trial. *Eur Heart J.* 2013; 34:3501-7

- 451 21. Cui R, Iso H, Yamagishi K, Tanigawa T, Imano H, et al. Ankle-arm blood
452 pressure index and cardiovascular risk factors in elderly Japanese men.
453 *Hypertens Res.* 2003; 26:377-382
- 454 22. Imano H, Kitamura A, Sato S, Kiyama M, Ohira T, et al. Trends for blood
455 pressure and its contribution to stroke incidence in the middle-aged Japanese
456 population: the Circulatory Risk in Communities Study (CIRCS). *Stroke.*
457 2009; 40:1571-1577
- 458 23. Kirkendall WM, Feinleib M, Freis ED, Mark AL. Recommendations for
459 human blood pressure determination by sphygmomanometers. Subcommittee
460 of the AHA Postgraduate Education Committee. *Circulation.* 1980; 62:1146A-
461 1155A
- 462 24. Nakamura M, Morita M, Yabuuchi E, Yukami M, Kuruma S, et al. The
463 evaluation and the results of cooperative cholesterol and triglyceride
464 standardization program by WHO-CDC. *Risho Byori.* 1982; 30:325–332 [in
465 Japanese]
- 466 25. American Diabetes Association. *Diagnosis and Classification of Diabetes*
467 *Mellitus.* *Diabetes Care.* 2010 Jan; 33(Suppl 1): S62–S69
- 468 26. Whitworth JA, World Health Organization, International Society of
469 Hypertension Writing Group. 2003 World Health Organization
470 (WHO)/International Society of Hypertension (ISH) statement on management
471 of hypertension. *J Hypertens.* 2003; 21:1983-92
- 472 27. Maruhashi T, Nakashima A, Soga J, Fujimura N, Idei N, et al. Hyperuricemia

473 is independently associated with endothelial dysfunction in postmenopausal
474 women but not in premenopausal women. *BMJ Open*. 2013; 3: e003659.

475 28. Teragawa H, Kato M, Kurokawa J, Yamagata T, Matsuura H, et al.
476 Usefulness of flow-mediated dilation of the brachial artery and/or the intima-
477 media thickness of the carotid artery in predicting coronary narrowing in
478 patients suspected of having coronary artery disease. *Am J Cardiol*. 2001,
479 15;88:1147-51.

480 29. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, et al. Relationship
481 between flow-mediated vasodilation and cardiovascular risk factors in a large
482 community-based study. *Heart*. 2013; 99:1837-1842

483 30. O'Neal WT, Efird JT, Yeboah J, Nazarian S, Alonso A, et al. Brachial Flow-
484 Mediated Dilation and Incident Atrial Fibrillation The Multi-Ethnic Study of
485 Atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2014; 34:2717-2720

486 31. Pastori D, Loffredo L, Perri L, Baratta F, Scardella L, et al. Relation of
487 nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated
488 dilation in patients with cardiometabolic risk factors. *Am J Cardiol*. 2015;
489 115:1402-1406

490 32. Lind L. Endothelium-dependent vasodilation in relation to different
491 measurements of blood pressure in the elderly: the prospective investigation of
492 the vasculature in Uppsala Seniors study. *Blood Press Monit*. 2008; 13:245-50

493 33. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, et al.
494 Central pressure: variability and impact of cardiovascular risk factors: the

495 Anglo-Cardiff Collaborative Trial II. Hypertension. 2008; 51:1476-1482

496 34. Jung CH, Jung SH, Kim KJ, Kim BY, Kim CH, et al. Differential
497 associations of central and brachial blood pressure with carotid atherosclerosis
498 and microvascular complications in patients with type 2 diabetes. BMC
499 Cardiovasc Disord. 2014; 14:23

500 35. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME. Selective
501 reduction of cardiac mass and central blood pressure on low-dose combination
502 perindopril/indapamide in hypertensive subjects. J Hypertens. 2004; 22:1623-
503 1630

504 36. Schiffrin EL. Circulatory therapeutics: use of antihypertensive agents and
505 their effects on the vasculature. J Cell Mol Med. 2010; 14: 1018–1029

506 37. Bots ML, Westerink J, Rabelink TJ, de Koning EJ. Assessment of flow-
507 mediated vasodilatation (FMD) of the brachial artery: effects of technical
508 aspects of the FMD measurement on the FMD response. Eur Heart J.
509 2005;26:363-8

510

511

512

513

514

515

516

Table 1. Mean values \pm standard deviations and proportions of cardiovascular risk factors among 507 Japanese men.

	Total number	%FMD		P for difference ^a
		≤ 5	> 5	
	507	153	354	
Mean % flow-mediated dilation	6.7 \pm 0.1	3.7 \pm 0.1	6.3 \pm 0.1	
%FMD ≤ 5 , n	153			
Brachial artery baseline diameter, mm	4.5 \pm 0.6	4.7 \pm 0.6	4.4 \pm 0.5	<0.01
Age, years	54.1 \pm 0.5	56.9 \pm 0.7	53.0 \pm 0.6	<0.0001
Body mass index, kg/m ²	24.2 \pm 0.2	24.3 \pm 0.3	24.2 \pm 0.2	0.6
Central aortic pressure, mmHg	124.5 \pm 0.8	127.9 \pm 1.4	123.1 \pm 0.9	<0.01
Systolic blood pressure, mmHg	129.2 \pm 0.7	132.1 \pm 1.3	127.9 \pm 0.9	0.05
Diastolic blood pressure, mmHg	82.3 \pm 0.5	83.2 \pm 0.8	82.6 \pm 0.6	0.56
Total cholesterol, mg/dL	202.2 \pm 1.5	200.2 \pm 2.7	203.0 \pm 1.7	0.47
Triglycerides, mg/dL	135.9 \pm 4.7	141.0 \pm 8.4	133.7 \pm 5.7	0.58
HDL-cholesterol, mg/dL	56.6 \pm 0.7	57.1 \pm 1.1	56.4 \pm 0.8	0.88
Current drinkers, %	74	76	73	0.02
Current smokers, %	33	37	31	0.31
Diabetes mellitus, %	8	12	7	0.07
Hypertension, %	35	45	31	<0.01
Antihypertensive medication use, %	26	35	21	<0.01

^a Chi-square test was used for categorical variables; ANOVA was used for continuous variables.

Table 2. Age- and multivariable-adjusted odds ratio (95% CI) of low FMD according to tertiles of central aortic pressure and systolic blood pressure in Japanese men.

	Tertiles of central systolic aortic pressure (mmHg)			OR per 1-SD increment ^b	Tertiles of brachial systolic blood pressure (mmHg)			OR per 1-SD increment ^b
	T1 (Low)	T2	T3 (High)		T1 (Low)	T2	T3 (High)	
Total subjects, No.	169	173	165		165	171	171	
Range of pressure	≤115	116-130	≥131		≤122	123-135	≥136	
Mean %FMD ± SD								
Age-adjusted %FMD	6.9±0.2	6.7±0.2	6.4±0.2		6.8±0.2	6.6±0.2	6.6±0.2	
Multivariable-adjusted %FMD ^a	6.8±0.2	6.8±0.2	6.4±0.2		6.6±0.2	6.6±0.2	6.7±0.2	
Low FMD, No.	41	51	61		44	53	56	
Age-adjusted OR	1	1.1(0.7-1.8)	1.5(0.9-2.4)	1.2(1.0-1.4)	1	1.0(0.6-1.7)	1.0(0.6-1.7)	1.2(0.9-1.4)
Multivariable-adjusted OR ^a	1	1.1(0.6-1.9)	1.5(0.9-2.6)	1.2(1.0-1.5)	1	0.9(0.5-1.6)	0.9(0.5-1.5)	1.0(0.8-1.3)
Subjects without antihypertensive medication use	142	124	111		145	127	105	
Range of pressure	≤113	114-128	≥129		≤118	119-132	≥133	
Mean %FMD ± SD								
Age-adjusted %FMD ± SD	7.3±0.3	6.9±0.3	6.6±0.3		7.2±0.3	6.8±0.3	6.8±0.3	
Multivariable-adjusted %FMD ± SD ^a	7.1±0.3	7.0±0.3	6.6±0.3		7.1±0.3	6.8±0.3	6.9±0.3	
Low FMD, No	29	32	38		30	38	31	
Age-adjusted OR	1	1.5(0.8-2.7)	2.0(1.1-3.7)	1.2(1.0-1.5)	1	1.3(0.7-2.3)	1.4(0.8-2.5)	1.1(0.9-1.4)
Multivariable-adjusted OR ^a	1	1.9(0.9-3.9)	2.4(1.2-4.8)	1.3(1.0-1.7)	1	1.2(0.7-2.3)	1.3(0.7-2.5)	1.1(0.8-1.4)
Subjects using antihypertensive medication	27	49	54		20	44	66	
Range of pressure	≤123	124-137	≥138		≤128	129-140	≥141	
Mean %FMD ± SD								
Age-adjusted %FMD ± SD	5.6±0.5	6.1±0.4	5.8±0.4		4.5±0.6	6.1±0.4	6.1±0.3	

Multivariable-adjusted %FMD \pm SD ^a	5.5 \pm 0.5	6.2 \pm 0.4	5.7 \pm 0.4		4.5 \pm 0.6	6.2 \pm 4	6.0 \pm 0.3	
Low FMD, No.	12	19	23		14	15	25	
Age-adjusted OR	1	1.2(0.5-2.8)	1.3(0.6-3.1)	1.1(0.8-1.5)	1	0.5(0.2-1.1)	0.8(0.3-1.8)	1.0(0.7-1.4)
Multivariable-adjusted OR ^a	1	1.1(0.4-3.0)	1.4(0.5-3.8)	1.2(0.8-1.8)	1	0.5(0.2-1.4)	0.8(0.3-2.2)	0.9(0.5-1.4)

1-SD for CAP= 16.3 mmHg, and 1-SD for SBP= 13.9 mmHg.

^a Adjusted for age, area of residence, heart rate, brachial artery baseline diameter, total serum cholesterol, serum triglycerides, history of diabetes mellitus, drinking status, and smoking status.

^b Calculated by linear regression analysis.